- Home
- UPXI vs CRVS Comparison
UPXI vs CRVS Comparison
Compare UPXI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- CRVS
- Stock Information
- Founded
- UPXI 2018
- CRVS 2014
- Country
- UPXI United States
- CRVS United States
- Employees
- UPXI N/A
- CRVS N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- CRVS Health Care
- Exchange
- UPXI Nasdaq
- CRVS Nasdaq
- Market Cap
- UPXI 481.8M
- CRVS 459.0M
- IPO Year
- UPXI 2021
- CRVS 2016
- Fundamental
- Price
- UPXI $6.33
- CRVS $5.88
- Analyst Decision
- UPXI
- CRVS Strong Buy
- Analyst Count
- UPXI 0
- CRVS 4
- Target Price
- UPXI N/A
- CRVS $15.00
- AVG Volume (30 Days)
- UPXI 5.9M
- CRVS 565.6K
- Earning Date
- UPXI 05-16-2025
- CRVS 11-11-2025
- Dividend Yield
- UPXI N/A
- CRVS N/A
- EPS Growth
- UPXI N/A
- CRVS N/A
- EPS
- UPXI N/A
- CRVS N/A
- Revenue
- UPXI $16,562,327.00
- CRVS N/A
- Revenue This Year
- UPXI $299.03
- CRVS N/A
- Revenue Next Year
- UPXI N/A
- CRVS N/A
- P/E Ratio
- UPXI N/A
- CRVS N/A
- Revenue Growth
- UPXI 1378.83
- CRVS N/A
- 52 Week Low
- UPXI $1.90
- CRVS $2.54
- 52 Week High
- UPXI $22.57
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- UPXI 48.40
- CRVS 59.43
- Support Level
- UPXI $5.20
- CRVS $5.90
- Resistance Level
- UPXI $6.84
- CRVS $6.09
- Average True Range (ATR)
- UPXI 0.73
- CRVS 0.33
- MACD
- UPXI -0.12
- CRVS -0.02
- Stochastic Oscillator
- UPXI 28.86
- CRVS 58.82
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via a Solana treasury strategy.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).